.Merck defeats profits desires, rears sales overview on strong requirement for top drugs like Keytruda CNBCMerck & Co. (MRK US) Defeats Earnings Projections as Keytruda Sales Increase BloombergMerck Stock: Pharma Giant Posts Powerful End Results, Yet Outlook Tumbles Short Client's Organization DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck defeats revenue as well as purchases desires amidst Keytruda strong point, but offers combined full-year expectation MarketWatch.